IP Library Granted Patent US 10,800,766
Granted Patent B2
US 10,800,766 · App. 16/436,843 · Granted Oct 13, 2020

Quinoline alkenes as cytoprotective agents

Inventor: Russell Dahl (Saint John, IN)
C07D409/06A61P3/10C07D215/06C07D215/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,800,766
App. No.
16/436,843
Granted
Oct 13, 2020
Kind
B2
Abstract

Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.

Claims (13)

1. A compound of Formula I:

or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; wherein:

R 2 is (a) hydrogen or (b) methyl;

R 4 , R 5 , and R 6 are each independently (a) hydrogen, cyano, or halo; (b) C 1-6 alkyl; or (c) —C(O)R 1a , C(O)OR 1a , C(O)NR 1b R 1c , —C(NR 1a )NR 1b R 1c , —OR 1a , —OS(O)NR 1b R 1c , —OS(O) 2 NR 1b R 1c , —NR 1b R 1c , —NR 1a C(O)R 1d , —NR 1a C(O)OR 1d , —NR 1a C(O)NR 1b R 1c , —NR 1a S(O)R 1d , —NR 1a S(O) 2 R 1d ;

each R 1a , R 1b , R 1c , and R 1d is independently (i) hydrogen or (ii) C 1-6 alkyl;

R 3 and R 7 are each independently (a) hydrogen or cyano; (b) C 1-6 alkyl; or (c) —C(O)R 1a , —C(O)OR 1a , —C(O)NR 1b R 1c , —C(NR 1a )NR 1b R 1c , —OR 1a , —OS(O)NR 1b R 1c , —OS(O) 2 NR 1b R 1c , —NR 1b R 1c , —NR 1a C(O)R 1d , —NR 1a C(O)OR 1d , —NR 1a C(O)NR 1b R 1c , —NR 1a S(O)R 1d , —NR 1a S(O) 2 R 1d ;

each R 1a , R 1b , R 1c , R 1d is independently (i) hydrogen or (ii) C 1-6 alkyl; and

R 1 is optionally substituted phenyl, thiophenyl, or furanyl; with the proviso that R 1 is not Ph, 4-NH 2 -Ph, 4-Me-Ph, 4-OMe-Ph, 4-Br-Ph, 4-OH-Ph, 4-COOMe-Ph, 4-CN-Ph, 4-Ph-Ph, 2-Naphthyl, or 4-NO 2 -Ph.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is methyl.

3. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 , R 4 , R 5 , R 6 , and R 7 are hydrogen.

4. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is methyl and R 3 , R 4 , R 5 , R 6 , and R 7 are hydrogen.

5. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is mono or disubstituted phenyl or mono or disubstituted 2-thienyl with the proviso that R 1 is not Ph, 4-Me-Ph, 4-OMe-Ph, 4-Br-Ph, 4-OH-Ph, 4-COOMe-Ph, 4-CN-Ph, 4-Ph-Ph, 2-Naphthyl, or 4-NO 2 -Ph.

6. The compound according to claim 1 selected from the group consisting of:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2021
From: DAHL, RUSSELL, DR
To: NEURODON CORPORATION
Reel/Frame 055251/0757 →
Continuity (3)
Continuation In Part 15361482 · Nov 27, 2016
Provisional Application 62260512 · Nov 28, 2015
Related Publication 20190375737A1 · Dec 12, 2019